Abstract
Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Current Signal Transduction Therapy
Title: Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Volume: 3 Issue: 3
Author(s): Simone Fulda
Affiliation:
Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists
Abstract: Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.
Export Options
About this article
Cite this article as:
Fulda Simone, Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs), Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699686
DOI https://dx.doi.org/10.2174/157436208785699686 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry The Relationship Between Lithium and Cancer Proliferation: A Case-Based Review of the Literature
Current Drug Metabolism Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Meet Our Editorial Board Member
Clinical Cancer Drugs Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Protein-Modified Magnetic Nanoparticles for Biomedical Applications
Current Organic Chemistry Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry